Generation Bio Co. (NASDAQ:GBIO) COO Sells $18,410.06 in Stock

Generation Bio Co. (NASDAQ:GBIO) COO Antoinette Paone sold 6,719 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $2.74, for a total value of $18,410.06. Following the completion of the sale, the chief operating officer now owns 13,807 shares in the company, valued at $37,831.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Generation Bio Price Performance

Shares of GBIO stock traded up $0.10 during trading hours on Wednesday, hitting $2.44. 184,668 shares of the company’s stock were exchanged, compared to its average volume of 233,135. Generation Bio Co. has a 52 week low of $0.86 and a 52 week high of $6.98. The stock has a market cap of $162.33 million, a price-to-earnings ratio of -0.92 and a beta of 2.84. The stock’s 50-day moving average is $3.07 and its 200-day moving average is $2.73.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings results on Monday, May 13th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.76). The company had revenue of $4.06 million for the quarter, compared to analyst estimates of $3.02 million. Generation Bio had a negative return on equity of 82.33% and a negative net margin of 1,696.87%. Equities research analysts forecast that Generation Bio Co. will post -1.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on GBIO shares. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Generation Bio in a research note on Tuesday, May 14th. Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a research report on Tuesday, May 14th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Generation Bio currently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Trading of Generation Bio

Several hedge funds have recently modified their holdings of GBIO. Artal Group S.A. raised its position in Generation Bio by 0.6% in the 1st quarter. Artal Group S.A. now owns 2,830,591 shares of the company’s stock worth $11,521,000 after purchasing an additional 16,400 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Generation Bio in the 1st quarter valued at $1,511,000. Yiheng Capital Management L.P. acquired a new stake in shares of Generation Bio in the 1st quarter valued at $780,000. Bellevue Group AG raised its position in shares of Generation Bio by 6.8% during the first quarter. Bellevue Group AG now owns 3,861,575 shares of the company’s stock worth $15,717,000 after acquiring an additional 244,495 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Generation Bio by 28.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,878,361 shares of the company’s stock valued at $36,136,000 after acquiring an additional 1,952,187 shares during the period. 95.22% of the stock is owned by institutional investors.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.